Key result
Cardiorenal syndrome stems from interacting hemodynamic and neurohormonal factors, endothelial dysfunction, inflammation, and uremia.
Why the study?
The complex interplay of hemodynamic, neurohormonal, endothelial, inflammatory, and uremic factors in the development of cardiorenal syndrome in congestive heart failure patients requires further elucidation for improved management.
This review highlights the complex interplay of hemodynamic, neurohormonal, and inflammatory factors in cardiorenal syndrome and outlines current and future therapeutic targets.
Answers are grounded in this paper and cite their sources.
Supports integrated cardiorenal strategies targeting multiple pathways; leaves open dominant driver validation in prospective trials.
The development of simultaneous decompensation in cardiac and renal function is a common phenomenon in patients with congestive heart failure. Termed the cardiorenal syndrome (CRS), this joint deterioration in cardiac output and renal filtration is the result of a complex interplay of hemodynamic and neurohormonal factors. Recently, endothelial dysfunction, inflammation and uremia have been recognized as contributors to the crosstalk responsible for the development of CRS. Management strategies for the treatment of CRS involve correction of hemodynamic derangements and regulation of neurohormonal pathways. Future therapies may target more newly recognized components of CRS pathophysiologic development.
No takes yet. Share an insight, caveat, or question.
Lisa Cohen (2014) conducted a review in Cardiorenal syndrome in congestive heart failure. Cardiorenal syndrome is driven by a complex interplay of hemodynamic and neurohormonal factors, alongside endothelial dysfunction, inflammation, and uremia.
Synapse has enriched 10 related papers. Consider them for comparative context: